Controversy over generic substitution

BMJ (Online)

Volumn 340, Issue 7760, 2010, Pages 1341-1343

  Ferner, R E ^a,b   Lenney, Warren ^c   Marriott, John F ^d  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^d ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHYLLINE; AMPHOTERICIN; BECLOMETASONE DIPROPIONATE; CARBAMAZEPINE; CITALOPRAM; CYCLOSPORIN; DILTIAZEM; ERYTHROMYCIN; FERROUS GLUCONATE; FERROUS SULFATE; GENERIC DRUG; IRON; LEVOTHYROXINE SODIUM; LITHIUM; MORPHINE SULFATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINE; NIFEDIPINE; PHENYTOIN; THEOPHYLLINE; VALPROIC ACID;

AREA UNDER THE CURVE; ARTICLE; COST CONTROL; DRUG BIOAVAILABILITY; DRUG COST; EYE DISEASE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MEDICAL DECISION MAKING; NATIONAL HEALTH SERVICE; PHARMACIST; PRIORITY JOURNAL; RASH; UNITED KINGDOM;

EID: 77953722299     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Department of Health. The proposals to implement 'generic substitution' in primary care, further to the Pharmaceutical Price Regulation Scheme (PPRS) 2009. www.dh.gov.uk/en/ Consultations/Liveconsultations/DH-110517.
2. Association of British Pharmaceutical Industries, UK Departments of Health. The pharmaceutical price regulation scheme 2009. www.dh.gov.uk/en/ Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-091825. (accessed 23rd March 2010).
3. Kalisch LM, Roughead EE, Gilbert AL. Brand substitution or multiple switches per patient? An analysis of pharmaceutical brand substitution in Australia. Pharmacoepidemiol Drug Safety 2008;17:620-5.
4. Vogler S, Habl C, Leopold C, Rosian-Schikuta I, de Joncheere K, Thomsen TL. Pharmaceutical pricing and reimbursement information (PPRI). European Commission, 2008. http:// ec.europa.eu/health/ph-projects/2004/action1/docs/ action1-2004-frep-05-en.pdf.
5. McCartney M. Generic drugs: protest group was not quite what it seemed. BMJ 2010;340:c1514
6. Faasse K, Cundy T, Petrie KJ. Thyroxine: anatomy of a health scare. BMJ 2009;339:b5613.
7. Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacotherap 2009;43:1583-97.
8. Danish Medicines Agency. Bioequivalence and labelling of medicinal products with regard to generic substitution. www.dkma.dk/1024/visUKLSArtikel. asp?artikelID=6437.
9. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, et al. The clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008;300:2514-26.
10. Borgheini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoative drugs. Clin Ther 2003;25:1578-92.
11. Welling PG, Koch PA, Lau CC, Craig WA. Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects. Antimicrobial Agent Chemotherapy 1977;11:462-9.
12. Kanazawa S, Ohkubo T, Sugawara K. The effects of grapefruit juice on the pharmacokinetics of erythromycin. Eur J Clin Pharmacol 2001;56:799-803.
13. Food and Drug Administration. Generic competition and drug prices. 2010. www.fda.gov/AboutFDA/CentersOffices/ CDER/ucm129385.htm.
14. Briesacher BA. Andrade SE. Fouayzi H. Chan KA. Medication adherence and use of generic drug therapies. Am J Managed Care 2009;15:450-6.
15. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008;336:1114-7.
16. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008;358:2457-67.